Mycoplasma genitalium (Mgen) infections treated using resistance guided therapy led to high cure rates and low levels of de novo resistance, according to latest data from Melbourne Sexual Health published in Clinical Infectious Diseases. Patients were initially given doxycycline and called back if tests were positive for Mgen.
The SpeeDx ResistancePlus® MG test was used and patients with macrolide susceptible infections received azithromycin while resistant infections received moxifloxacin. Although the population demonstrated 71.5% macrolide resistance, a 95.4% cure rate was achieved.
Read the Infectious Disease Advisor summary.